Compare ALX & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALX | DMRA |
|---|---|---|
| Founded | 1928 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 1994 | 2020 |
| Metric | ALX | DMRA |
|---|---|---|
| Price | $261.77 | $28.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $43.00 |
| AVG Volume (30 Days) | 15.7K | ★ 466.5K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $213,183,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $280.22 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $201.28 | $16.50 |
| 52 Week High | $289.43 | $34.89 |
| Indicator | ALX | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.95 | 51.33 |
| Support Level | $229.61 | $22.71 |
| Resistance Level | $271.02 | $34.89 |
| Average True Range (ATR) | 7.37 | 2.13 |
| MACD | -2.61 | -0.44 |
| Stochastic Oscillator | 37.90 | 9.51 |
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing, and redeveloping its properties. It has five properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City, which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.